ANN ARBOR, MI / ACCESS Newswire / August 13, 2026 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic solutions for equine and companion animals, today announced a collaboration with Boehringer Ingelheim Animal Health Canada Inc., a leader in the animal health industry, to enhance the early detection, treatment, and monitoring of pituitary pars intermedia dysfunction (PPID) in horses across Canada. "Veterinarians play a critical role in recognizing and managing PPID, and we've seen the meaningful difference that early diagnosis, treatment, and whole-horse management can make," commented Randy Trumpler, Business Unit Director - Equine at Boehringer Ingelheim Animal Health Canada Inc.